A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

WEDNESDAY, Nov. 12, 2024 (HealthDay News) -- Overtreatment of prostate cancer is increasing in the United States among men with limited life expectancy, a new study reports. Procedures like radiation ...

Please provide your email address to receive an email when new articles are posted on . A new model showed greater accuracy at predicting prostate cancer mortality vs. existing tools. It incorporates ...

A large German cohort study finds that adherence to key lifestyle recommendations is associated with up to 32% lower mortality rate among long-term cancer survivors.

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

The city says it will devote $2 million to improve health outcomes, including for Black men in particular, who have Boston’s lowest life expectancy.

Thousands of men suffering from prostate cancer are set to gain access to a life-extending drug on the NHS following a significant expansion of eligibility criteria. Previously, the hormone therapy ...